<DOC>
	<DOCNO>NCT00408590</DOCNO>
	<brief_summary>RATIONALE : A gene-modified virus may able kill tumor cell without damage normal cell . PURPOSE : This phase I trial study side effect best dose attenuate oncolytic measles virus therapy oncolytic virus therapy treat patient progressive , recurrent , refractory ovarian epithelial cancer primary peritoneal cancer ( measles virus vaccine therapy study close 06/02/2008 ) .</brief_summary>
	<brief_title>Recombinant Measles Virus Vaccine Therapy Oncolytic Virus Therapy Treating Patients With Progressive , Recurrent , Refractory Ovarian Epithelial Cancer Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety toxicity recombinant carcinoembryonic antigen ( CEA ) -expressing measles virus ( MV-CEA ) oncolytic measles virus encode thyroidal sodium iodide symporter ( MV-NIS ) patient progressive , recurrent , refractory ovarian epithelial primary peritoneal cavity cancer ( MV-CEA close 06/02/2008 ) . - Determine maximum-tolerated dose MV-CEA MV-NIS patient ( MV-CEA close 06/02/2008 ) . - Characterize viral gene expression dose level manifest CEA titer patient . - Assess viremia , viral replication , measles virus shed persistence study therapy . - Determine humoral cellular immune response inject virus patient . - Assess , preliminarily , antitumor efficacy therapy , assess CA-125 level , radiographic response , time progression , patient . - Determine time course viral gene expression virus elimination biodistribution virally infected cell various time point infection MV-NIS use single photon emission compute tomography ( SPECT/CT ) imaging . - Assess viremia , viral replication , measles virus shedding/persistence follow intraperitoneal administration MV-NIS . OUTLINE : This dose-escalation study . Patients receive recombinant carcinoembryonic antigen-expressing measles virus ( MV-CEA ) oncolytic measles virus encode thyroidal sodium iodide symporter ( MV-NIS ) intraperitoneally 30 minute day 1 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity ( MV-CEA close 06/02/2008 ) . Cohorts 3-6 patient receive escalate dos MV-CEA maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity ( MV-CEA close 06/02/2008 ) . Peripheral blood mononuclear cell collect baseline periodically treatment assess viremia . Throat gargle urine specimen assess periodically course 1 viral shed reverse transcriptase-polymerase chain reaction ( RT-PCR ) . Peritoneal aspirate test baseline periodically treatment viral replication RT-PCR , co-culture Vero cell , measles virus N-specific mRNA situ hybridization . Patients may undergo single photon emission compute tomography ( SPECT/CT ) image baseline periodically study . After completion study therapy , patient follow periodically 15 year . PROJECTED ACCRUAL : A total 46 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Age ≥ 18 year . Must persistent , recurrent progressive ovarian cancer primary peritoneal cancer prior treatment platinum taxol compound . Histologic confirmation original primary tumor require . Prior bilateral oophorectomy require . Patients follow histologic epithelial cell type eligible : Serous adenocarcinoma , endometroid adenocarcinoma , mucinous adenocarcinoma , undifferentiated carcinoma , clear cell adenocarcinoma , mixed epithelial carcinoma , transitional cell carcinoma , malignant Brenner 's Tumor , adenocarcinoma NOS The following laboratory value obtain ≤7 day prior registration : ANC ≥ 1500/μL PLT ≥ 100,000/μL Total bilirubin ≤ upper normal limit AST ≤ 2 x ULN Creatinine ≤ 1.5 x ULN Hgb ≥ 9.0 g/dL Ability provide inform consent . Willingness return Mayo Clinic Rochester followup . Life expectancy ≥ 12 week . Must antimeasles immunity demonstrate serum IgG antimeasles antibody level ≥ 20.0 EU/ml determine Enzyme Immunoassay ( Diamedix , FL ) . Must normal serum CEA level ( &lt; 5 mg/ml ) time study entry prior test . ( NOTE : Not applicable MVNIS cohort . ) Willingness provide biologic specimen require protocol . Measurable disease exam CT scan , , patient CA125 elevation microscopic residual without measurable disease imaging , willingness undergo laparoscopy evaluation treatment effect radiographic progression 6 treatment cycle . CD4 count ≥200/μL ≥15 % peripheral blood lymphocyte Exclusion criterion : Epithelial tumor low malignant potential , stromal tumor , germ cell tumor ovary . Known standard therapy patient 's disease potentially curative definitely capable extend life expectancy . Subjects exclude first relapse recur &gt; 6 mo completion primary ( adjuvant ) chemotherapy . ECOG performance status ( PS ) 3 4 . Active infection ≤5 day prior registration . History tuberculosis history PPD positivity . History malignancy ≤5 year except nonmelanoma skin cancer carcinoma situ cervix . Any following prior therapy : Chemotherapy ≤ 3 week prior study entry Immunotherapy ≤ 4 week prior study entry Biologic therapy ≤ 4 week prior study entry Extensive abdominal surgery include enterotomy ( y ) &lt; 3 week prior study entry . This criterion apply placement peritoneal portacath lysis adhesion time study entry . Any viral gene therapy prior study entry Failure fully recover acute , reversible effect prior chemotherapy regardless interval since last treatment . New York Heart Association classification III IV , know symptomatic coronary artery disease , symptom coronary artery disease system review , know cardiac arrhythmia ( atrial fibrillation SVT ) . Requiring blood product support . CNS metastases seizure disorder . HIVpositive test result , history immunodeficiency . History organ transplantation . History chronic hepatitis B C. Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFDAapproved indication context research investigation ) . Any concurrent medication could interfere trial . Intraabdominal disease &gt; 8 cm diameter time registration , intrahepatic disease , disease beyond abdominal cavity . Treatment oral/systemic corticosteroid , exception topical inhaled steroid . Exposure household contact ≤15 month old household contact know immunodeficiency . Allergy measles vaccine history severe reaction prior measles vaccination . Allergy iodine . This include reaction intravenous contrast material .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>Brenner tumor</keyword>
</DOC>